CalciMedica Secures FDA Alignment on Auxora Phase 2b Trial Design, Establishing Acute Pancreatitis’s First Potential Registrational Endpoints

CalciMedica, Inc. (NASDAQ: CALC), a clinical-stage biopharmaceutical company developing CRAC channel inhibition therapies for serious inflammatory, immunologic, and cardiopulmonary diseases, announced on July 29, 2026 that following a Type C Focused Meeting, the FDA aligned with CalciMedica on Phase 2b trial endpoints and a patient population enrichment strategy for Auxora in acute pancreatitis. The agreement identifies potential registrational endpoints for the disease and establishes a regulatory blueprint for a planned U.S. pivotal program in AP. A CRO is engaged and potential clinical sites are under discussion, with the trial still in preparation.

Acute Pancreatitis Has No Approved Treatment and a Severe Unmet Need

Acute pancreatitis causes roughly 300,000 hospitalizations in the United States each year, making it one of the most common gastrointestinal causes of hospital admission. In severe cases, inflammatory injury spreads beyond the pancreas into the lungs and other organs, producing life-threatening respiratory failure. No approved pharmacological therapy exists to modify the disease course. Physicians manage AP supportively, addressing pain, hydration, and organ failure as they emerge, but have no drug to interrupt the underlying inflammatory cascade. That absence creates the regulatory opportunity CalciMedica is now formalizing: the FDA and CalciMedica have agreed on new-onset severe respiratory failure as the primary endpoint for the Phase 2b trial, with multi-organ failure and time to medically indicated discharge as key secondary endpoints, a clinically meaningful outcome set that addresses the leading driver of AP mortality.

CRAC Channel Inhibition Targets the Vascular Injury at AP’s Core

Auxora inhibits CRAC channels, which regulate calcium entry into endothelial cells and drive the vascular injury and inflammation seen across acute inflammatory diseases, including AP. In AP, that endothelial injury is believed to contribute to new-onset severe respiratory failure, a major driver of mortality and morbidity in the disease. The Phase 2b CARPO trial, published in eClinicalMedicine in 2025, enrolled 214 patients and established a dose response across multiple endpoints, identified the target patient population and optimal dose for a pivotal program, and confirmed Auxora’s safety profile across more than 350 critically ill patients dosed to date. The new Phase 2b will prospectively evaluate elevated lactate dehydrogenase (LDH) as an enrichment marker, supported by CARPO data linking LDH above 240 U/L to higher IL-6 levels and more respiratory failure events, giving the registrational program a higher probability of detecting a treatment effect on the agreed primary endpoint.

Financing Update and the KOURAGE Risk to Weigh

Investors should weigh the AP milestone against two additional considerations. On the financing side, CalciMedica reported $8.2 million in cash at March 31, 2026 before closing a private placement of up to approximately $49 million in June 2026, with an upfront tranche of approximately $15 million extending cash runway into the second half of 2027. Today’s press release confirms the planned PAH program is supported by proceeds from that June 2026 financing, materially improving the company’s near-term capital position relative to earlier guidance. Additional tranches remain subject to conditions, so dilution risk is reduced but not eliminated. On the clinical side, KOURAGE, a Phase 2 trial in AKI with respiratory failure, paused enrollment in January 2026 after an Independent Monitoring Committee flagged a mortality imbalance. CalciMedica and external experts found no evidence of drug-related toxicity, and the FDA raised no objection to resuming dosing under an amended protocol, but the company currently has no plans to resume dosing and is evaluating the program’s future.

Strategic Investment Summary

• FDA Alignment: CalciMedica (NASDAQ: CALC) secured FDA agreement on Phase 2b trial endpoints and a patient enrichment strategy for Auxora in acute pancreatitis on July 29, 2026, following a Type C Focused Meeting.
• First Potential Registrational Endpoints: New-onset severe respiratory failure is the agreed primary endpoint, with multi-organ failure and time to medically indicated discharge as key secondary endpoints, establishing a clinically meaningful target set for a planned U.S. pivotal program in AP.
• CARPO Foundation: The Phase 2b CARPO trial (214 patients, published in eClinicalMedicine 2025) established dose response, identified the target patient population and optimal dose, and confirmed safety across more than 350 critically ill patients dosed, directly informing the LDH-based enrichment strategy the FDA endorsed.
• Trial Status: The Phase 2b AP trial is still in preparation; a CRO is engaged and potential sites are under discussion, with no start date yet announced.
• Financing Position: A June 2026 private placement of up to approximately $49 million, with an upfront tranche of approximately $15 million, extends runway into H2 2027 and supports the planned AP and PAH programs. Additional tranches remain subject to conditions, so dilution risk is reduced but not eliminated.
• KOURAGE Risk: The KOURAGE AKI trial paused in January 2026 after an IMC flagged a mortality imbalance; no drug-related toxicity was identified, but CalciMedica currently has no plans to resume dosing and is evaluating the program’s future.

Find out more about the latest clinical updates and financial reports at the CalciMedica investor portal.